Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma

被引：23
|
作者：
Young, Kate [1 ]
Smyth, Elizabeth [1 ]
Chau, Ian [1 ]
机构：
[1] Royal Marsden Hosp, Gastrointestinal Oncol Unit, Sutton SM2 5PT, Surrey, England
来源：
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2015年 / 8卷 / 06期
关键词：
angiogenesis; gastric cancer; gastro-oesophageal cancer; ramucirumab; vascular endothelial growth factor; vascular endothelial growth factor receptor 2; RANDOMIZED PHASE-III; 2ND-LINE CHEMOTHERAPY; 1ST-LINE THERAPY; SUPPORTIVE CARE; DOUBLE-BLIND; OPEN-LABEL; GROWTH; COMBINATION; PLUS; VEGF;
D O I：
10.1177/1756283X15592586
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides a valuable additional treatment option.
引用
收藏
页码：373 / 383
页数：11
相关论文
共 50 条
  • [1] Ramucirumab use in patients with advanced gastric cancer (AGC) or gastro-oesophageal junction (GEJ) adenocarcinoma in Spain: RAMIS observational study
    Longo Munoz, F.
    Jorge Fernandez, M.
    Tur, R. Yaya
    Diaz, S.
    Ortega, M.
    Dilla, T.
    Molero, A.
    Cervera, J. M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] Ramucirumab plus paclitaxel as a second-line treatment for advanced gastric or gastro-oesophageal junction cancer
    Nature Reviews Gastroenterology & Hepatology, 2014, 11 (11) : 642 - 642
  • [3] ECONOMIC EVALUATION OF RAMUCIRUMAB AS SECOND-LINE CHEMOTHERAPY FOR PREVIOUSLY TREATED ADVANCED GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION ADENOCARCINOMA IN CHINA
    Luo, X.
    Peng, L.
    Tan, C.
    Wan, X.
    Zeng, X.
    VALUE IN HEALTH, 2018, 21 : S33 - S33
  • [4] Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma
    Connie Kang
    Targeted Oncology, 2023, 18 (6) : 981 - 989
  • [5] Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma
    Kang, Connie
    TARGETED ONCOLOGY, 2023, 18 (06) : 981 - 989
  • [6] Adjuvant nivolumab for gastric and gastro-oesophageal junction cancer
    Petrelli, Fausto
    Celotti, Andrea
    Dottorini, Lorenzo
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (12): : 1079 - 1079
  • [7] The ATTRACTION of nivolumab for gastric and gastro-oesophageal junction cancer
    Katrina Ray
    Nature Reviews Gastroenterology & Hepatology, 2017, 14 (12) : 690 - 690
  • [8] Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Buyukkaramikli, Nasuh C.
    Blommestein, Hedwig M.
    Riemsma, Rob
    Armstrong, Nigel
    Clay, Fiona J.
    Ross, Janine
    Worthy, Gill
    Severens, Johan
    Kleijnen, Jos
    Al, Maiwenn J.
    PHARMACOECONOMICS, 2017, 35 (12) : 1211 - 1221
  • [9] Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Nasuh C. Büyükkaramikli
    Hedwig M. Blommestein
    Rob Riemsma
    Nigel Armstrong
    Fiona. J. Clay
    Janine Ross
    Gill Worthy
    Johan Severens
    Jos Kleijnen
    Maiwenn J. Al
    PharmacoEconomics, 2017, 35 : 1211 - 1221
  • [10] Health state utility values associated with advanced gastric, oesophageal, or gastro-oesophageal junction adenocarcinoma: a systematic review
    Carter, Gebra Cuyun
    King, Denise T.
    Hess, Lisa M.
    Mitchell, Stephen A.
    Taipale, Kaisa-Leena
    Kiiskinen, Urpo
    Rajan, Narayan
    Novick, Diego
    Liepa, Astra M.
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (11) : 954 - 966
12345